Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285779 · ClinicalTrials.gov registry record · Phase 2
Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00285779: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00285779 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00285779, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with lichen planus.
Interventions
- DRUG Placebo
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285779
The ClinicalTrials.gov registry entry for NCT00285779 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00285779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00285779 about?
NCT00285779 is a clinical study titled "Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus". The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with...
What is the current status of trial NCT00285779?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2006-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00285779?
The interventions under investigation include: Placebo (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT00285779?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.